Maravai LifeSciences (MRVI) Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last twelve months. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MRVI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRVI, but not buy additional shares or sell existing shares.
View MRVI analyst ratings or view top-rated stocks.

9 Wall Street analysts have issued 1 year price targets for Maravai LifeSciences' stock. Their MRVI share price forecasts range from $8.00 to $24.00. On average, they predict the company's share price to reach $14.10 in the next twelve months. This suggests a possible upside of 41.0% from the stock's current price.
View analysts price targets for MRVI or view top-rated stocks among Wall Street analysts.

Maravai LifeSciences' stock was trading at $14.31 on January 1st, 2023. Since then, MRVI stock has decreased by 30.1% and is now trading at $10.00.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our MRVI earnings forecast.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) released its quarterly earnings data on Monday, August, 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.04. The business had revenue of $68.91 million for the quarter, compared to analyst estimates of $70.30 million. Maravai LifeSciences had a net margin of 13.88% and a trailing twelve-month return on equity of 20.67%.

ETFs with the largest weight of Maravai LifeSciences (NASDAQ:MRVI) stock in their portfolio include Morningstar US Small Growth (MSGR), Janus Henderson Small Cap Growth Alpha ETF (JSML), First Trust Health Care AlphaDEX Fund (FXH) and Putnam BioRevolution ETF (SYNB).WisdomTree U.S. SmallCap Fund (EES).

Maravai LifeSciences issued an update on its FY 2023 earnings guidance on Monday, August, 7th. The company provided EPS guidance of $0.04-$0.08 for the period, compared to the consensus EPS estimate of $0.29. The company issued revenue guidance of $300.00 million-$325.00 million, compared to the consensus revenue estimate of $403.92 million.

(MRVI) raised $1.3 billion in an initial public offering (IPO) on Friday, November 20th 2020. The company issued 50,000,000 shares at $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs served as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers.

Maravai LifeSciences trades on the NASDAQ under the ticker symbol "MRVI."

Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRVI stock can currently be purchased for approximately $10.00.

Maravai LifeSciences (NASDAQ:MRVI) has a market capitalization of $2.51 billion and generates $883 million in revenue each year. The company earns $220.21 million in net income (profit) each year or $0.57 on an earnings per share basis.

The company employs 660 workers across the globe.

Maravai LifeSciences' mailing address is 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.maravai.com. The company can be reached via phone at 858-546-0004 or via email at ir@maravai.com.